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Alzheimer’s disease (AD) is a neurodegenerative disorder responsible for the majority of dementia cases in elderly people. It is
widely accepted that the main hallmarks of AD are not only senile plaques and neurofibrillary tangles but also reactive
astrogliosis, which often precedes detrimental deposits and neuronal atrophy. Such phenomenon facilitates the regeneration of
neural networks; however, under some circumstances, like in AD, reactive astrogliosis is detrimental, depriving neurons of the
homeostatic support, thus contributing to neuronal loss. We investigated the presence of reactive astrogliosis in 3×Tg-AD mice
and the effects of palmitoylethanolamide (PEA), a well-documented anti-inflammatory molecule, by in vitro and in vivo studies.
In vitro results revealed a basal reactive state in primary cortical 3×Tg-AD-derived astrocytes and the ability of PEA to
counteract such phenomenon and improve viability of 3×Tg-AD-derived neurons. In vivo observations, performed using
ultramicronized- (um-) PEA, a formulation endowed with best bioavailability, confirmed the efficacy of this compound.
Moreover, the schedule of treatment, mimicking the clinic use (chronic daily administration), revealed its beneficial
pharmacological properties in dampening reactive astrogliosis and promoting the glial neurosupportive function. Collectively,
our results encourage further investigation on PEA effects, suggesting it as an alternative or adjunct treatment approach for
innovative AD therapy.
1. Introduction
Alzheimer’s disease (AD) accounts for more than 80% of
dementia cases worldwide in elderly people and leads to
the progressive loss of mental, behavioral, and learning abil-
ities and to functional decline [1]. Histopathologically, AD
is characterized by two major protein deposits affecting
mainly hippocampal and cortical regions: extracellular neu-
ritic β-amyloid peptide (Aβ), which induces the creation of
senile plaques (SPs), and the production of intracellular
neurofibrillary tangles (NFTs) due to tau hyperphosphory-
lation that occupies much of the cytoplasm of pyramidal
neurons [2, 3]. The presence of abnormally activated
microglia and astrocytes is a feature of AD of more recent
discovery [4]. It is followed by an intense inflammation,
closely associated with amyloid deposits in the brain paren-
chyma [4, 5]. Indeed, studies of post mortem brain tissues
from AD patients demonstrated the presence of a general-
ized astrogliosis, mainly manifested by astrocytic dysfunc-
tion, detectable by an increased expression of both glial
fibrillary acidic protein (GFAP) and S100B, and accompa-
nied by an increased production of proinflammatory medi-
ators [6]. Many authors name this complex phenomenon as
reactive astrogliosis [6, 7]. GFAP is a specific cytoskeletal
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marker, whose expression is higher during astrogliosis [8].
S100B is a neurotrophin that, at physiological concentrations
(nanomolar), exerts prosurvival effects on neurons and
stimulates neurite outgrowth [9]. However, at higher
(micromolar) concentrations, S100B becomes neurotoxic,
promoting inflammation and neuronal apoptosis [10]. Aβ
itself induces the expression of proinflammatory cytokines
by glial cells [11] and the induction of proinflammatory
enzymes, such as the inducible nitric oxide synthase
(iNOS) and the isoenzyme cyclooxygenase type-2 (COX-
2). Several lines of evidence suggest that all these factors
may contribute to neuronal dysfunction and cell death,
either alone or in concert [12]. The reactive astrogliosis
has the initial intent of defence of removing injurious
stimuli. However, if this phenomenon goes beyond physi-
ological control, it may cause several detrimental effects.
Under these circumstances, both neuronal and synaptic loss
are detectable, because structural and functional modifica-
tions of neurons and astrocytes occur [13, 14]. Alterations
of the neuronal marker microtubule-associated protein 2
(MAP-2), as well as modifications of the neurotrophin
brain-derived neurotrophic factor (BDNF) content, have also
been demonstrated [15, 16]. Considering the crucial actions
of BDNF, especially in controlling neuronal survival, differ-
entiation, neurotransmitter release, dendritic remodeling,
axon growth, and synaptic plasticity [17, 18], the detri-
mental consequences of its alterations by reactive astrogliosis
may be dramatic.
Based on this evidence, it is reasonable to assume that an
early combination of neuroprotective and anti-inflammatory
treatments may represent an efficacious approach to counter-
act AD. In this context, palmitoylethanolamide (PEA), an
endogenous lipid mediator, seems to be a promising pharma-
cological agent. The anti-inflammatory and neuroprotective
effects of PEA, as well as its ability to attenuate memory
impairment in surgical models of AD, have already been
demonstrated [15, 19–22].
In this work, we provide novel evidence on the ability
of PEA to counteract reactive astrogliosis and neuronal
impairment both in vitro and in vivo. For the in vitro
studies, we used primary cortical neurons and astrocytes
from 3×Tg-AD mice, a triple transgenic model of AD cur-
rently considered the closest to the familial human disease,
and from wild-type littermates (non-Tg). The same AD
model was used for the in vivo experiments, in which male
3-month-old 3×Tg-AD and sex- and age-matched non-Tg
mice were subcutaneously implanted with a pellet, releas-
ing either ultramicronized-PEA (um-PEA) or placebo, for
three months. This treatment schedule was designed to
reproduce a chronic treatment (as needed for this type
of disease), administered starting from the early stage of
the AD pathology.
In vitro results highlighted an intense activation and
inflammation in primary 3×Tg-AD astrocytes, as well as
the ability of PEA to counteract them and promote neu-
ronal viability. Moreover, in vivo biochemical experi-
ments demonstrated that chronic um-PEA treatment
resulted in a beneficial control of the astrocyte activation
and neuroinflammation. In addition, um-PEA interestingly
increased BDNF levels, confirming its neuroprotective/neu-
rotrophic effects.
Our results confirm the therapeutic potential of PEA,
demonstrating its ability to counteract some of the detri-
mental effects occurring in AD, since the earliest stage of
the pathology. PEA is already on the market for the
treatment of pain. Therefore, these observations, in addi-
tion to the information regarding its safety and tolerability
also in humans, prompt us to hypothesize a rapid translation
into clinical practice.
2. Materials and Methods
All the procedures involving animals were conducted in con-
formity with the guidelines of the Italian Ministry of Health
(D.L. 26/2014) and performed in compliance with the Euro-
pean Parliament directive 2010/63/EU.
2.1. Animals and Experimental Design. 3×Tg-AD mice [23]
expressing APPswe, PS1M146V, and tauP301L human trans-
genes were compared to non-Tg littermates. The background
strain of 3×Tg-AD mice was C57BL6/129SvJ hybrid [23].
Animals were group housed and raised in controlled condi-
tions (22± 2°C temperature, 12 h light/12 h dark cycle,
50%–60% humidity) in an enriched environment, with food
and water ad libitum.
For in vitro experiments, we used newborn mice at post-
natal day (PND) 1 or 2. Astrocytes were isolated from both
non-Tg (total pups used= 12) and 3×Tg-AD (total pups
used =24) mice. Neurons were isolated from 3×Tg-AD mice
(total pups used= 12).
For in vivo experiments, 3-month-old male non-Tg
(n = 18) and 3×Tg-AD (n = 18) mice were used. Animals
were surgically implanted with a 90-day-release pellet con-
taining either 28mg um-PEA, a formulation that improves
its bioavailability [24], or placebo (catalogue number NX-
999 and NC-111, resp.; Epitech Group SpA). Both pellets
were made by Innovative Research of America (Sarasota,
Florida) that homogeneously distributed um-PEA in the
matrix, keeping its original crystalline form of micrometric
size. Therefore, mice received 10mg/kg/day for 3 consecu-
tive months. Experimental dosage was chosen according to
literature [25, 26].
To subcutaneously implant the pellet, mice were anesthe-
tized with ketamine hydrochloride (1mg/10 g) and xylazine
(0.1mg/10 g). After shaving the shoulder blades, the implan-
tation area was sterilized with 70% alcohol. A dorsal midline
incision of 1-2 cm was executed to create a subcutaneous
pocket with a blunt probe. One pellet, containing um-PEA
or placebo, was placed into the pocket and the surgical inci-
sion was closed with sterile absorbable sutures. Non-Tg and
3×Tg-ADmice were then left in their home cages for the next
three months, and their weight monitored daily. No weight
differences among all experimental groups were detected
(data not shown). At the end of the chronic treatment, 6-
month-old mice were killed by decapitation, and their brains
were rapidly excised and either immediately frozen on dry ice
for the immunofluorescence experiments or freshly dissected
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to isolate the frontal cortex (FC) for RT-PCR and Western
blot analyses.
The experimental timelines are summarized in Figure 1.
2.2. Astroglial Primary Cultures. Astroglial primary cultures
were obtained as previously described [27]. Cortices were
isolated from non-Tg and 3×Tg-AD newborn mice (PND
1 or 2) sacrificed by decapitation. Tissues were manually
homogenized in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 5% inactivated fetal bovine
serum (FBS), 100U/ml penicillin and 100μg/ml streptomy-
cin and then chemically dissociated with a solution contain-
ing 0.25% trypsin, 0.2% ethylenediaminetetraacetic acid
(EDTA), and 0.2mg/ml of DNAse I (all from Sigma-Aldrich,
Milan, Italy) to obtain single cells. After a centrifugation
at 403×g for 5 minutes, the medium was replaced, and
surviving cells were counted using a Burker chamber with
a 0.2% trypan blue solution and seeded at a density of
3× 10−6 cells/75 cm2 flask. Cell cultures were at +37°C in
humidified atmosphere containing 5% CO2. DMEM supple-
mented with 20% inactivated FBS and 100U/ml penicillin,
and 100μg/ml streptomycin was replaced 24 h and one week
after isolation. Approximately 14-15 days after the dissection,
when a monolayer of cells was created, astrocytes were
separated from microglia by mechanical shacking. Then,
astrocytes were detached from the plates with a solution
containing 0.25% trypsin and 0.2% EDTA and then seeded
into 10 cm diameter petri dishes at a density of 1× 106 cells/
dish for Western blot analysis, into eight chambers polysty-
rene culture slides at a density of 3× 104 cells/chamber
(Thermo Fisher Scientific, MA, USA) for immunofluores-
cence, or into 24-well plates at a density of 1× 105 cells/well
for neutral red viability assay. Experiments were performed
28 days after cells isolation, when astrocytes are considered
completely mature [22].
2.3. Neuronal Primary Cultures. Cortices from newborn
3×Tg-AD mice (PND 1 or 2) were used to obtain primary
neuronal cultures as previously described [20]. Multiwells
were previously coated with poly-L-lysine (Sigma-Aldrich)
to allow neurons to adhere to the bottom of the wells. Mice
were sacrificed by decapitation and cerebral cortices dis-
sected in Hank’s balanced salt solution (HBSS) containing
25mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(Hepes), 100U/ml penicillin, and 100μg/ml of streptomycin
in cold conditions. Tissues were mechanically and chemically
homogenized in a solution containing 0.25% trypsin, 0.2%
EDTA, and 0.2mg/ml of DNAse I (all from Sigma). After a
centrifugation at 403×g for 5 minutes, cells were suspended
in neurobasal media supplemented with 2% B27, 100U/ml
penicillin, and 100μg/ml streptomycin. Then, they were
counted using a Burker chamber while suspended in 0.2%
trypan blue solution and then seeded in 24-well multiplates
at a density of 5× 10−5 cells/well. Neuronal cultures were
maintained at +37°C in humidified atmosphere containing
5% CO2. Twenty-four hours later, cells were treated with
10μM of cytosine arabinoside (ara-C) to suppress glial cell
growth. One week later, primary 3×Tg-AD-derived neurons
were treated with PEA.
2.4. Chemicals and Cell Treatments. Mature astrocytes and
neurons derived from 3×Tg-AD mice were treated with
PEA (Epitech Group SpA, Saccolongo, Italy), at three differ-
ent concentrations (0.01, 0.1, and 1μM), chosen according to
our previous works [19, 20, 22]. PEA was suspended in 5%
pluronic F-68 (Sigma-Aldrich) and solubilized in 95%
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Figure 1: Study designs. Schematic representation of the experimental designs in (a) primary 3×Tg-AD and non-Tg astrocytes, (b) primary
3×Tg-AD neurons, and (c) in vivo experiments in 3×Tg-AD and non-Tg mice.
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DMEM. First, we added pluronic F-68 to PEA powder and
sonicated the emulsion for 20min protecting it from light,
and then we included DMEM to complete the solution. Via-
bility assay, Western blot analysis, and immunofluorescence
were performed 24 h after treatments.
2.5. Analysis of Astrocyte and Neuronal Viability by Neutral
Red Uptake Assay. Astrocyte and neuronal viability was
tested 24h after treatment by neutral red uptake assay, as
previously described [27]. Cells were incubated with a neutral
red working solution, containing 50μg/ml in Ca2+ and Mg2-
free PBS (Sigma-Aldrich), for 3 h at +37°C. Cells were then
rinsed in Ca2+- and Mg2-free PBS and the dye removed from
the inside of the cells through a rinse in destaining solution
(ethanol : deionized water : glacial acetic acid, 50 : 49 : 1 v/v).
The absorbance, whose value is proportional to the number
of living cells, was read at 540nm using a microplate spectro-
photometer (Epoch, BioTek, Winooski, VT, USA). The
values obtained were referred to control medium-exposed
cultures (CTRL) and expressed as percentage variation of
CTRL. Three independent experiments were performed
in triplicate.
2.6. Immunofluorescence. Both primary astrocytes, 24 h after
treatment, and non-Tg and 3×Tg-AD coronal slices (12μm
thickness), deriving from 6-month-old mice containing the
FC, were rinsed in PBS and postfixed for 10 minutes at
+4°C with 4% paraformaldehyde (PFA) prepared in PBS.
Then, samples were blocked with 1% bovine serum albumin
(BSA) prepared in PBS/0.25% triton X-100 for 90 minutes at
room temperature. Cells were incubated overnight at +4°C in
0.5% BSA in Tris-buffered saline (TBS)/0.25% triton X-100
solution containing the primary antibodies rabbit anti-
GFAP (1 : 1000, Abcam, Cambridge, USA) or rabbit anti-
S100B (1 : 250, Novus Biologicals, Littleton, CO, USA). FC
slices, instead, were incubated overnight at +4°C with mouse
anti-MAP2 (1 : 250, Novus Biologicals, Littleton, CO, USA)
in 0.5% BSA in TBS/0.25% triton X-100 solution. The
following day, cells and tissues were thoroughly rinsed
in PBS and then incubated for 2 hours at room temper-
ature with the appropriate secondary antibody (fluores-
cein- (FITC-) conjugated AffiniPure goat anti-rabbit IgG
(H+L), rhodamine- (TRITC-) conjugated AffiniPure goat
anti-rabbit IgG (H+L), 1 : 200, or rhodamine- (TRITC-)
conjugated AffiniPure goat anti-mouse IgG (H+L); Jackson
ImmunoResearch, Suffolk, UK). Nuclei were stained with
4′,6-diamidino-2-phenylindole, dihydrochloride (DAPI)
(1 : 75000, Sigma-Aldrich) in 0.5% BSA in TBS/0.25% tri-
ton X-100, added to the solution of the secondary antibod-
ies. Samples were rinsed with PBS and coverslipped using
Fluoromount aqueous mounting medium (Sigma-Aldrich).
Experimental conditions are summarized in Table 1.
Pictures were captured with a wide-field microscope
(Eclipse E600; Nikon Instruments, Rome, Italy) and densito-
metric analysis performed using ImageJ software. Data are
expressed as ratio (ΔF/F0) of the difference between the mean
of fluorescence sample and its background (ΔF) and the non-
immunoreactive regions (F0). To prevent the observation of
differences among experimental groups due to artifacts, the
exposure parameters, such as gain and time, were kept
constant during image acquisitions. For each analysis, three
replicates were used, and at least three independent experi-
ments were performed.
2.7. RNA Isolation and RT-PCR. Total mRNA from FC of
both non-Tg and 3×Tg-AD mice was extracted using the
NZY total RNA isolation kit (NZYTech, Lisboa, Portugal)
following the manufacturer’s protocol. Total mRNA was
quantified by Nanodrop 1000 spectrophotometer (Thermo
Fisher Scientific, MA, USA). Revers transcription of 1μg
mRNA was performed to obtain cDNA adding oligo(dT)
and random primers to the first-strand cDNA synthesis
kit (NZYTech, Lisboa, Portugal). All PCRs were performed
using the supreme NZYTaq DNA polymerase (NZYTech,
Lisboa, Portugal) in the presence of specific primers
(Sigma-Aldrich) for the target genes: GFAP, GAPDH,
S100B, iNOS, and COX-2. GAPDH was used as reference
gene. Three independent experiments were performed in
triplicate. Primer sequences and PCR details are reported
in Table 2.
2.8. Protein Extraction and Western Blot Analysis. Western
blot analysis was performed on protein extracts obtained
from primary astrocytic cultures as well as from FC samples,
as previously described [15]. Samples were suspended in ice-
cold hypotonic lysis buffer containing 50mM Tris/HCl
pH7.5, 150mM NaCl, 1mM EDTA, 1% triton X-100,
1mM phenylmethylsulfonyl fluoride (PMSF), 10μg/ml
aprotinin, and 0.1mM leupeptin (all from Sigma-Aldrich).
After 40min of incubation at +4°C, homogenates were cen-
trifuged at 18440×g for 30min and the supernatant collected
and stored in aliquots at −80°C until use. An equivalent
Table 1: Experimental conditions for immunofluorescence.
Primary
antibody
Brand primary
antibody
Primary antibody
dilution
Secondary antibody
Brand secondary
antibody
Rabbit α-GFAP Abcam
1 : 1000 0.5% BSA in
TBS/0.25% triton X-100
FITC conjugated goat anti-rabbit IgG (H+L) 1 : 200,
0.5% BSA in TBS/0.25% triton X-100
Jackson
ImmunoResearch
Rabbit α-S100B
Novus
Biologicals
1 : 250 0.5% BSA in
TBS/0.25% triton X-100
TRITC conjugated goat anti-rabbit IgG (H+L) 1 : 200,
0.5% BSA in TBS/0.25% triton X-100
Jackson
ImmunoResearch
Mouse α-MAP2
Novus
Biologicals
1 : 250 0.5% BSA in
TBS/0.25% triton X-100
TRITC conjugated goat anti-mouse IgG (H+L) 1 :
200, 0.5% BSA in TBS/0.25% triton X-100
Jackson
ImmunoResearch
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amount of each sample (50μg), calculated by Bradford assay,
was resolved through 12% acrylamide SDS-PAGE precast
gels (Bio-Rad Laboratories, Segrate, Italy). Then, with a
trans-blot SD semidry transfer cell (Bio-Rad Laboratories),
proteins were transferred onto nitrocellulose membranes
that were then blocked with 5% no-fat dry milk powder or
5% BSA in TBS 0.1% Tween 20 (TBS-T) (Tecnochimica
Moderna, Rome, Italy) for 1 h before overnight incubation
at +4°C with the appropriate primary antibodies. After
appropriate rinses in 0.05% TBS-T, membranes were incu-
bated for 1 h at room temperature with a specific secondary
horseradish peroxidase- (HRP-) conjugated antibody. The
experimental conditions are summarized in Table 3.
Immunocomplexes were detected by an ECL kit (GE
Healthcare Life Sciences, Milan, Italy), exposed to X-ray film
(GE Healthcare Life Sciences, Milan, Italy) and quantified
using ImageJ software. Protein expression level of β-actin
was used as loading control. For each antibody, three repli-
cates were used, and at least three independent experiments
were performed.
2.9. Statistical Analysis. Analysis was performed using
GraphPad Prism software (GraphPad Software, San Diego,
CA, USA). Student’s t-test was used to compare two groups.
One-way analysis of variance (ANOVA) was used to deter-
mine statistical differences among experimental groups in
in vitro experiments. In vivo results were analyzed by
two-way ANOVA, with genotype and treatment as factors.
Bonferroni’s post hoc test was used upon detection of a main
significant effect. Differences between mean values were
considered statistically significant when P < 0 05.
3. Results
3.1. 3×Tg-AD Primary Astrocytes Present Reactive
Astrogliosis. Reactive astrogliosis is a phenomenon com-
monly detectable in AD brains and characterized by both
astrocyte activation and neuroinflammation [6]. Here, we
decided to test parameters connected with such events in
both non-Tg and 3×Tg-AD primary astrocytes.
Table 3: Experimental conditions for Western blot from 3×Tg-AD mice astrocytes and FC.
Primary antibody
Brand primary
antibody
Dilution Secondary antibody
Brand secondary
antibody
GFAP Abcam
1 : 50000 5% milk
in TBS-T 0.1%
HRP conjugated goat anti-rabbit
IgG 1 : 30000 5% milk in TBS-T 0.1%
Jackson
ImmunoResearch
S100B Novus Biologicals
1 : 1000 5% BSA in
TBS-T 0.1%
HRP conjugated goat anti-rabbit
IgG 1 : 10000 5% BSA in TBS-T 0.1%
Jackson
ImmunoResearch
COX-2 Cell Signaling
1 : 1000 5% milk in
TBS-T 0.1%
HRP conjugated goat anti-rabbit
IgG 1: 10000 5% milk in TBS-T 0.1%
Jackson
ImmunoResearch
iNOS Sigma-Aldrich
1 : 8000 1% BSA in
TBS-T 0.1%
HRP conjugated goat anti-rabbit
IgG 1 : 10000 1% BSA in TBS-T 0.1%
Jackson
ImmunoResearch
BDNF Santa Cruz
1 : 500 5% milk in
TBS-T 0.1%
HRP conjugated goat anti-rabbit
IgG 1 : 10000 5% milk in TBS-T 0.1%
Jackson
ImmunoResearch
MAP2 Novus Biologicals
1 : 250 5% BSA in
TBS-T 0.1%
HRP conjugated goat anti-rabbit
IgG 1 : 10000 5% BSA in TBS-T 0.1%
Jackson
ImmunoResearch
Aβ(1–42) Millipore
1 : 1000 5% BSA in
TBS-T 0.1%
HRP conjugated goat anti-mouse
IgG 1 : 10000 5% BSA in TBS-T 0.1%
Jackson
ImmunoResearch
β-actin Santa Cruz
1 : 1500 5% milk in
TBS-T 0.1%
HRP conjugated goat anti-rabbit
IgG 1 : 10000 5% milk in TBS-T 0.1%
Jackson
ImmunoResearch
Table 2: Primer sequences used for RT-PCR.
Sequence of interest Primer 5′→3′ Annealing temperature (°C) Number of cycles
GFAP
Forward GAAGAGGGACAACTTTGCAC
61 32
Reverse GCTCTAGGGACTCGTTCGTG
S100B
Forward TAATGTGAGTGGCTGCGGAA
63 32
Reverse CCTCACCAAGGGCTAAGCAG
iNOS
Forward CAAGCTGATGGTCAAGATCCAGAG
64 40
Reverse GTGCCCATGTACCAACCATTGAAG
COX-2
Forward GCTGTACAAGCAGTGGCAAA
62 30
Reverse CCCCAAAGATAGCATCTGGA
GAPDH
Forward GCTACACTGAGGACCAGGTTGTC
64 30
Reverse CCATGTAGGCCATGAGGTCCAC
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To study astrocyte activation, we tested the expression
of GFAP, a specific cytoskeletal marker, and S100B, a neu-
rotrophin that when present at high concentrations
becomes neurotoxic [6, 28, 29]. Results obtained from both
immunofluorescence and Western blot analysis showed a
significantly higher GFAP immunoreactivity in primary
3×Tg-AD astrocytes than non-Tg cells (immunofluores-
cence: P < 0 05; Western blot P < 0 01) (Figures 2(a), 2(b),
2(e), and 2(f)), while we did not detect changes in S100B
signal (P > 0 05) (Figures 2(c), 2(d), 2(e), and 2(g)).
A neuroinflammatory environment is mainly character-
ized by the production and activation of two inducible
enzymes: the prostanoid-generating enzyme COX-2 and
iNOS [15]. Here, we tested the expression of these two
enzymes in non-Tg and 3×Tg-AD primary astrocytes.
Results showed that iNOS expression is significantly higher
in transgenic-derived primary astrocytes than non-Tg cells
(P < 0 01) (Figures 2(e) and 2(h)). We did not find any
statistical difference in COX-2 expression between the two
experimental groups (P > 0 05) (Figures 2(e) and 2(i)).
Collectively, these results show that reactive astrogliosis is
detectable in mature 3×Tg-AD cortical astrocytes.
3.2. PEA Improves Neuronal Viability and Counteracts
Reactive Astrogliosis In Vitro. To test whether PEA treat-
ment could have any toxic effect on astrocyte and neuro-
nal viability, we performed the neutral red assay. Results
showed that PEA did not affect astrocytes or neuronal via-
bility at all concentrations tested (P > 0 05) (Figures 3(a)
and 3(b)). Surprisingly, the highest PEA concentration sig-
nificantly improved neuronal viability (+5.35%; P < 0 001)
(Figure 3(b)).
Next, we tested the ability of PEA, at different concen-
trations (0.01, 0.1, and 1μM), to counteract reactive astro-
gliosis. Western blot analyses showed that PEA treatment
prevented GFAP increase in primary astrocytes derived from
newborn 3×Tg-ADmice in a concentration-dependent man-
ner (P < 0 05) (Figures 3(c) and 3(d)). Results by immunoflu-
orescence confirmed this trend, although only the highest
dose of PEA reached statistical significance (P < 0 05)
(Figures 3(f) and 3(g)). Moreover, by Western blot, we found
that 1μM PEA was able to significantly reduce iNOS expres-
sion (P < 0 05) (Figures 3(c) and 3(e)).
These results show that PEA has no toxicity in both
astrocytes and neurons from 3×Tg-AD mice, at the con-
centrations tested; rather, it promotes neuron viability.
Moreover, PEA counteracts reactive astrogliosis in mature
3×Tg-AD primary astrocytes.
3.3. Chronic Um-PEA Normalizes Reactive Astrogliosis in
the Frontal Cortex of 3×Tg-AD Mice. Given the interesting
in vitro results, and with the aim of further exploring
PEA effectiveness in the triple transgenic model of AD,
we decided to translate the study in vivo. Specifically, we
tested the effect of chronic um-PEA treatment on reactive
astrogliosis and neuronal functionality in FCs of 6-month-
old 3×Tg-AD mice, compared to their age-matched non-
Tg littermates.
Confirming our in vitro observations, we found astrocyte
activation in FC of 3×Tg-ADmice when compared with their
age-matched non-Tg littermates. Indeed, we found, by RT-
PCR and Western blot, an increase of both GFAP and
S100B expression in placebo-treated 3×Tg-AD mice in
comparison with placebo-treated non-Tg mice (P < 0 05)
(Figures 4(a), 4(b), 4(c), 4(f), 4(g), and 4(h)). Um-PEA
chronic treatment greatly controlled such astrocytic activa-
tion, significantly decreasing GFAP mRNA and protein
expression (P < 0 05) (Figures 4(a), 4(b), 4(f), and 4(g)).
Moreover, the two-way ANOVA showed a significant
genotype-by-treatment interaction effect on GFAP transcrip-
tion (Fgenotype×treatment(1,23) = 7.872, P = 0 0062) (Figure 4(g))
and expression (Fgenotype×treatment(1,23) = 4.829, P = 0 0337)
(Figure 4(g)). Surprisingly, um-PEA also induced a trend
toward a decrease (−20%) of S100B protein expression in
3×Tg-AD mice compared to placebo-treated 3×Tg-AD ones
(Figures 4(a), 4(c), 4(f), and 4(h)).
Regarding the parameters related to the inflammatory
process, RT-PCR and Western blot results showed a signifi-
cant increase of iNOS transcription (P < 0 001) (Figures 4(a)
and 4(d)) and expression (P < 0 05) (Figures 4(f) and 4(i))
in the FC of placebo-treated 3×Tg-AD mice in comparison
with placebo-treated non-Tg animals. Interestingly, chronic
um-PEA treatment greatly controlled the induced produc-
tion of this proinflammatory enzyme (RT-PCR: P < 0 001;
Western blot: P < 0 05) (Figures 4(a), 4(d), 4(f), and 4(i)).
In addition, two-way ANOVA showed a significant
genotype-by-treatment interaction effect in iNOS transcrip-
tion (Fgenotype×treatment(1,23) = 28.37, P < 0 0001) (Figure 4(d))
and protein expression (Fgenotype×treatment(1,23) = 4.894, P =
0 0306) (Figure 4(i)). As in in vitro results, neither geno-
type nor treatment induced changes in COX-2 transcript
and protein expression (Figures 4(a), 4(e), 4(f), and 4(j)).
Interestingly, using Western blot experiments, we
found a trend toward an increase of Aβ(1–42) (+20%) in
the FCs of transgenic mice in comparison with the non-
Tg animals. This trend, which follows the observed
changes in parameters related to astrocyte activation and
neuroinflammation, is in line with the evidence available
in literature indicating that 6-month-old 3×Tg-AD mice
show Aβ overexpression predominantly in FC layers 4 to
5 [23]. Moreover, chronic um-PEA treatment dampened
the expression of Aβ in 3×Tg-AD mice, although this
failed to reach significance (−34.23%) (Figures 4(f) and
4(k)). Despite this evidence, further experiments will be
required to demonstrate the existence of a causative corre-
lation between the reduction of Aβ load and the control of
neuroinflammation.
Combined, our results demonstrate the presence of acti-
vated astrocytes and a proinflammatory environment in the
FCs of 3×Tg-AD mice at 6 months of age. Additionally, we
show that chronic um-PEA treatment efficaciously controls
these alterations in the AD brain.
3.4. Chronic um-PEA Normalizes Astrocyte Support to
Neuronal Functionality in the Frontal Cortex of 3×Tg-AD
Mice. Finally, we wanted to explore if there was any
impairment in neuronal functionality guided by astrocytes
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Figure 2: Study of parameters related to reactive astrogliosis in 3×Tg-AD and non-Tg primary astrocytes. (a) Representative fluorescent
photomicrographs of GFAP (green) and (b) signal quantification in both non-Tg (white bar) and 3×Tg-AD (black bar) primary
astrocytes. (c) Representative fluorescent photomicrographs of S100B (red) and (d) signal quantification in both non-Tg (white bar) and
3×Tg-AD (black bar) primary astrocytes. Nuclei were stained with DAPI (blue). Scale bar is 50μm. Fluorescence analysis is expressed as
ΔF/F0. (e) Representative bands and Western blot densitometric analysis of (f) GFAP, (g) S100B, (h) iNOS, and (i) COX-2. β-Actin was
used as loading control. Results are expressed as percentage of the mean control value (non-Tg cells). Experiments were performed three
times in triplicate. Data are presented as mean± SEM. The statistical analysis was performed by Student’s t-test (∗P < 0 05 and ∗∗P < 0 01
versus non-Tg group).
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Figure 4: Effect of chronic um-PEA on reactive astrogliosis and Aβ(1–42) expression in the FC of 3×Tg-AD and non-Tg mice. (a)
Representative bands from RT-PCR performed in FC homogenates for GFAP, S100B, iNOS, and COX-2, and (b–e) densitometric analysis
of the corresponding signals normalized to GAPDH. (f) Representative immunoreactive species and Western blot densitometric analysis
of (g) GFAP, (h) S100B, (i) COX-2, (j) iNOS, and (k) Aβ(1–42). β-Actin was used as loading control. Results are expressed as percentage
of the mean control value (non-Tg/placebo). Experiments were performed three times in triplicate. Data are presented as mean± SEM.
The statistical analysis was performed by two-way ANOVA followed by Bonferroni’s post hoc multiple comparison test (∗P < 0 05 and
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that is responsible for BDNF production [30]. To address
this goal, we tested both BDNF and MAP2 expression.
Western blot analysis showed an impaired production
of BDNF in the FC of placebo-treated 3×Tg-AD ani-
mals compared to placebo-treated non-Tg littermates.
Interestingly, um-PEA significantly counteracted such
decrease (P < 0 05) (Figures 5(a) and 5(b)). Surprisingly,
these modifications did not affect neuronal survival.
Indeed, by both Western blot and immunofluorescence,
we did not observe modifications in MAP2 expression in
placebo-treated transgenic mice in comparison with
placebo-treated non-Tg animals (Figures 5(a), 5(c), 5(d),
and 5(e)).
Altogether, these results demonstrate the presence of
reduced trophic support to FC neurons in 6-month-old
3×Tg-AD mice; this has not yet impaired neuronal via-
bility. Chronic um-PEA treatment restores the neuronal
trophic support.
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Figure 5: Effect of chronic um-PEA on neuronal support and survival in FC of 3×Tg-AD and non-Tg mice. (a) Representative
immunoreactive species and Western blot densitometric analysis of (b) BDNF and (c) MAP2. β-Actin was used as loading
control. Results are expressed as percentage of the mean control value (non-Tg/placebo). (d) Representative fluorescent
photomicrographs of MAP2 (red) staining in FC of 6-month-old non-Tg and 3×Tg-AD mice, placebo- or um-PEA-treated.
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4. Discussion
Astrocytes represent the crucial element of a defensive sys-
tem of CNS. Cerebral insults trigger reactive astrogliosis,
which represents a conserved defensive reprogramming of
astroglial cells. It is a very heterogeneous phenomenon that
limits damage and facilitates postlesion regeneration of neu-
ral networks [31–33], although it may become neurotoxic in
some circumstances [34]. In fact, astrogliosis involves com-
plex biochemical and functional remodelling and produces
multiple reactive cellular phenotypes. The common feature
of pathological astroglial change is the morphological cellular
remodelling towards atrophy or hypertrophy [35, 36]. This
sometimes occurs at early pathological stages preceding
(and possibly precipitating) neuronal death. Such an early
activation is observed in AD, when astrocytes, in proximity
of plaques and β-amyloid deposits, acquire a reactive pheno-
type detectable by an increased expression of intermediate
filaments and overproduction of proinflammatory mediators
[23, 35, 37]. By this way, astrocytes contribute to neurode-
generation, becoming interesting targets for the development
of innovative therapies [38–41]. Here, we provide the first
in vitro evidence of the presence of a basal reactive state in
primary astrocytes derived from 3×Tg-AD mice cortices, as
well as of the capability of PEA to counteract such a phenom-
enon and improve neuronal viability. We also obtained
important data on the beneficial pharmacological properties
of this compound by testing the effect of a chronic treatment
with um-PEA in 3×Tg-AD mice. Our in vivo results indicate
that, during the mild stage of the disease, both reactive astro-
gliosis and neuroinflammation are already detectable in the
FCs of transgenic animals, and that chronic um-PEA is able
to alleviate both indices.
Several clinical studies have shown that an impairment
of hippocampus, entorhinal cortex, posterior cingulate
gyrus, amygdala, and parahippocampal gyrus occur in
early AD [42–45]. When AD becomes severe, atrophy pro-
gresses from the hippocampus to the FC [46]. Interestingly,
our results revealed the absence of neuronal atrophy in
6-month-old 3×Tg-AD mice (age that corresponds to a
mild stage of pathology), but detected the early presence
of reactive astrogliosis, confirming that such phenomenon
is precocious and comes before neuronal loss in this
animal model.
Since glial cells, previously considered only space-filling
support cells of the CNS, are indeed highly involved in the
maintenance of CNS homeostasis, we wondered whether
cells in the FC were abnormally activated during the mild
stage of the disease, before atrophy occurs. To this aim, we
first performed an in vitro screening of 3×Tg-AD cortical
astrocytes and compared them with non-Tg-derived cells,
for signs of astrocyte activation and inflammation. In the
absence of any exogenous insult, 3×Tg-AD primary astro-
cytes showed a basal reactive and proinflammatory pheno-
type, as demonstrated by the increased expression of GFAP
and iNOS, a cytoskeletal astrocyte marker and a proinflam-
matory inducible enzyme, respectively. Since reactive gliosis
may occur before plaque formation, these results suggest that
astrocytes can contribute to AD progression before the
development of the main AD hallmarks [40]. Since some
astrocytes express little or no GFAP [47], we used an addi-
tional astrocytic marker, such as S100B, a Ca2+-binding pro-
tein. S100B is a neurotrophic factor that improves neuronal
survival during CNS development [48]. In adulthood, levels
of S100B increase after brain damage and can be neurotoxic
and proinflammatory [49]. We did not find any genotypic
difference in S100B expression, in our experimental condi-
tion. Therefore, it is possible that this protein maintains
trophic functionality in the cell population analysed in the
absence of an actual injury. Moreover, to further evaluate
the inflammatory component in this animal model, we
studied a proinflammatory enzyme, COX-2, responsible for
prostanoid formation. Its involvement in the cascade of
events leading to neurodegeneration in AD is still controver-
sial [50]. COX-2 expression did not change in 3×Tg-AD
cortical astrocytes, confirming the hypothesis that COX-2
induction could be connected with neurotoxicity [51], but
this was not assessed in this in vitro study.
In the last few years, increasing evidence has confirmed
the effectiveness of PEA treatment against inflammation in
different models of neurodegeneration [15, 21, 52, 53]. Here,
we tested the effectiveness of this compound on those
parameters that we found to be influenced by the 3×Tg-AD
genotype. Therefore, first we demonstrated the absence of
astrocytic and neuronal toxicity of PEA at three different
concentrations (0.01, 0.1, and 1μM). Then, we performed
the neutral red assay, a viability test, in both primary
astrocytes and primary neurons, confirming that PEA is not
cytotoxic and fosters neuronal viability at the highest concen-
tration investigated. This result agrees with the already
proven neuroprotective effects of PEA in different preclinical
models of neurological disorders [15, 54, 55]. In a surgical rat
model of AD, we recently demonstrated the ability of PEA to
counteract the reactive gliosis caused by Aβ(1–42) hippocam-
pal infusion [15]. Here, we demonstrated that PEA exerts this
pharmacological effect in a transgenic model of AD, expand-
ing the range of pathological targets treatable with this
compound. In fact, the present in vivo experiments
confirmed the therapeutic potential of chronic PEA adminis-
tration. Moreover, such experiments were designed to
simulate a clinic-like treatment schedule; for this reason,
3-month-old 3×Tg-AD and sex- and age-matched non-
Tg animals were chronically treated for three months with
placebo or um-PEA, a crystalline form on micrometric size,
which improves its pharmacokinetics properties [24, 56].
Consistent with our in vitro observations, in the FC of
3×Tg-AD mice, we detected the presence of reactive gliosis
in the mild stage of the disease, as shown by the increased
transcription and expression of both GFAP and iNOS. The
expression of both S100B and COX-2 were not affected by
the genotype. Only S100BmRNAwas increased in transgenic
cortices. Interestingly, chronic um-PEA treatment dampened
such alterations, confirming its effectiveness against reactive
gliosis in vivo. Another interesting result was the detection
of lower levels of BDNF in the FC of transgenic mice in com-
parison with non-Tg littermates, and, even more significant,
the discovery of the ability of chronic um-PEA at increasing
the expression of BDNF. Despite the fact that we found a
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decreased expression of BDNF together with the presence of
reactive gliosis, known to be able to amplify CNS damages
[14, 47], we did not detect any impairment of neuronal via-
bility in FC of 3×Tg-AD mice. Such evidence was surprising
because it is widely accepted that at 6 months of age these
transgenic mice show early symptoms of AD-like pathology
and behavioural alterations [23, 57–59]. However, since
CNS impairment in AD travels broadly from hippocampus
to FC, we can speculate that the massive alteration of this
brain region has not occurred as yet, and neurons can some-
how survive these insults. In fact, Castello and colleagues
demonstrated that BDNF reduction does not exacerbate Aβ
and tau pathology, but is a consequence of the pathology
itself [60]. If this is true, the improvement in BDNF produc-
tion that we found in mice after chronic um-PEA treatment
can be a positive sign of the control that such a molecule
has on the pathology in its entirety, and not only against
reactive gliosis.
5. Conclusions
In the present study, we expand the knowledge on glial
activity in a triple transgenic model of AD that closely
mimics the main features of the pathology. Here, we provide
the first evidence that 3×Tg-AD mice present signs of reac-
tive gliosis in the FC at an early stage of the disease. More-
over, we demonstrate for the first time that acute PEA
in vitro, as well as chronic um-PEA in vivo, may counteract
such phenomenon, improving the trophic support to neu-
rons, in absence of astrocytes and neuronal toxicity. By the
virtue of its safety [61], and considering the growing body
of evidence regarding its efficacy, we foresee a possible trans-
lation of the results collected in animal models into the
clinical practice, in the near future.
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